Log in
RegisterPatient population for bioequivalence study [Regulatives / Guidelines]
Dear All
We are planning to conduct a bioequivalence study in patient population for USFDA submission.
As per product label, the drug is used in three indications (i.e. diseases)
Out of three indication, patients comprise of two indication are difficult to recruit, because of disease criticality & severity. However for third indication, patients are abundantly available for the enrollment in to the BE study.
Considering the above fact, is it necessary to conduct bioequivalence study in all eligible patient population as per label or we can recruit only patients for third indication. Will there be any regulatory concerns in term of BE acceptance, product approval & getting marketing authorization for all indication.
Kindly share your view.
We are planning to conduct a bioequivalence study in patient population for USFDA submission.
As per product label, the drug is used in three indications (i.e. diseases)
Out of three indication, patients comprise of two indication are difficult to recruit, because of disease criticality & severity. However for third indication, patients are abundantly available for the enrollment in to the BE study.
Considering the above fact, is it necessary to conduct bioequivalence study in all eligible patient population as per label or we can recruit only patients for third indication. Will there be any regulatory concerns in term of BE acceptance, product approval & getting marketing authorization for all indication.
Kindly share your view.
Complete thread:
- Patient population for bioequivalence studypash413 2017-10-04 15:44 [Regulatives / Guidelines]
![[Mix]](https://static.bebac.at/img/mix.png "open in Mix view")
- Patient population for bioequivalence study DavidManteigas 2017-10-06 10:34
- Patient population for bioequivalence study pash413 2017-10-06 15:33
- Patient population for bioequivalence study DavidManteigas 2017-10-06 10:34
Ing. Helmut Schütz